BridgeMD
New treatment option for Obesity
Official title Food Intake-Related Brain and Metabolic Responses in Obesity
ClinicalTrials.gov ID: NCT07392905
What this study is testing
- What it's testing
- This study is a prospective, single-center, randomized, controlled, crossover intervention trial. A total of 60 participants, including 30 patients with obesity and 30 healthy controls, will be enrolled.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40. Healthy volunteers may be eligible.
You may be able to join if
- Obese participants:
- BMI ≥ 28 kg/m²;
- Age 18-40 years;
- Any gender;
- Right-handed. Healthy control participants:
You likely can't join if
- Diabetes mellitus;
- Contraindications or allergies to any ingredient in the standardized meal or macronutrient challenges used in this study;
- Central nervous system disorders (e.g., traumatic brain injury, acute cerebral infarction, epilepsy) or psychiatric disorders (e.g., depression...
- Severe impairment of liver, kidney, heart, or gastrointestinal function, including alanine aminotransferase (ALT) and/or aspartate aminotransferase...
- Contraindications to MRI, such as implanted metallic devices or claustrophobia;
- Pregnancy or lactation;
See the full eligibility criteria
- Obese participants:
- BMI ≥ 28 kg/m²;
- Age 18-40 years;
- Any gender;
- Right-handed. Healthy control participants:
- BMI 18.5-23.9 kg/m²;
- Age 18-40 years;
- Any gender;
- Right-handed.
- Diabetes mellitus;
- Contraindications or allergies to any ingredient in the standardized meal or macronutrient challenges used in this study;
- Central nervous system disorders (e.g., traumatic brain injury, acute cerebral infarction, epilepsy) or psychiatric disorders (e.g., depression, schizophrenia); use of medications acting on the central nervous system...
- Severe impairment of liver, kidney, heart, or gastrointestinal function, including alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels \>2 times the upper limit of normal; estimated glomerular...
- Contraindications to MRI, such as implanted metallic devices or claustrophobia;
- Pregnancy or lactation;
- Participation in another clinical trial currently or within the past 3 months; use of nutritional supplements within the past 3 months or long-term use;
- History of prior metabolic/bariatric surgery;
- Use of antibiotics or probiotics within the past 1 month;
- Use of medications affecting metabolism or causing weight loss within the past 1 month; body weight fluctuation exceeding 3 kg during the month prior to screening;
- Unusual dietary habits; daily alcohol intake \>40 grams, smoking \>10 cigarettes per day, or coffee consumption ≥2 cups per day.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 40 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.